EAHAD 2023: Treatments Show Promise for Hemophilia A and B
At EAHAD 2023, researchers reported positive results from trials of patients with hemophilia A and B, including those who are difficult to treat.
Bleeding Disorders
BLEEDING DISORDERS
LATEST ARTICLES
Results With N8-GP Within Range for Previously Untreated Pediatric Patients With Hemophilia A
Researchers sought to determine whether inhibitor incidence with N8-GP prophylaxis would be within range for patients with previously untreated hemophilia A.
Study Shows Positive Long-Term Efficacy and Safety With Romiplostim for Immune Thrombocytopenia
Researchers sought to determine whether romiplostim would be effective in treating pediatric patients with immune thrombocytopenia.
FDA Extends Review Period for Valoctocogene Roxaparvovec for Hemophilia A
Valoctocogene roxaparvovec is an investigational adeno-associated virus (AAV) gene therapy.
Gene Therapy Etranacogene Dezaparvovec Shows Favorable Safety for Patients With Hemophilia B
Researchers sought to determine whether etranacogene dezaparvovec would be safe for treating patients with hemophilia B.
Altuviiio Approved as Once-Weekly Factor VIII Therapy for Hemophilia A
Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis.
Study Finds Many Mothers of Children With Hemophilia Experience Guilt
Researchers sought to assess experiences of guilt and coping strategies in mothers of children with hemophilia.
Emicizumab Appears Safe, Effective in Patients With Mild or Moderate Hemophilia A
Researchers sought to determine whether emicizumab would be effective in patients with non-severe hemophilia A without inhibitors.
Efanesoctocog Alfa Prophylaxis Highly Effective in Hemophilia A
Researchers sought to determine whether efanesoctocog alfa would be effective as bleeding prophylaxis for patients with severe hemophilia A.
Women With Immune Thrombocytopenia Show No Increased Risk of Severe Bleeding During Pregnancy
Researchers sought to determine whether women with ITP have an increased risk of severe bleeding during pregnancy.
Researchers Develop Reliable Predictor for Perioperative Diagnosis of Acquired VWS in Infants With Congenital Heart Disease
Researchers sought to investigate diagnostic tools of acquired VWS compared with multimer analysis as diagnostic criterion standard.
Recent Data Shows Prophylaxis Is Initiated at a Younger Age for Patients With Severe Hemophilia
Researchers sought to determine whether there were any changes in prophylactic treatment practices among previously untreated patients with hemophilia.
A1 Domain Required for Assembly of Von Willebrand Factor Tubules With in Vivo Helical Parameters
Researchers sought to determine the role of the A1 domain of the VWF glycoprotein in VWF tubule assembly.
Problem Joints Are Associated With Worse Quality of Life and Work-Productivity Loss in Adults With Hemophilia
Researchers sought to assess the impact of problem joints in patients with hemophilia.
Haplotype Mismatch Unrelated to Anti-Factor VIII Antibody Binding in Hemophilia A
Researchers sought to determine whether a mismatch between F8 gene haplotypes impacted antibody binding to factor VIII in patients with hemophilia A.
Researchers Address Kinesiophobia in Patients With Hemophilia
Researchers sought to evaluate effects of kinesiophobia among patients with hemophilia.
Long-Term Risk of ITP Higher in Patients With Persistent, Isolated Mild Thrombocytopenia
Researchers sought to assess the risk of progression to ITP or hematologic neoplasia in adults with persistent, isolated mild thrombocytopenia.
Emicizumab Is Safe and Effective in Infants With Severe Hemophilia A
Researchers sought to determine whether emicizumab would be effective in treating infants with severe hemophilia A without factor VIII inhibitors.
Factor VIII Concentrate With an Extended Half-Life for Patients With Hemophilia A
Researchers sought to determine whether using factor VIII concentrate with an extended half-life would improve outcomes in patients with hemophilia A.
First Gene Therapy for Hemophilia B Gets FDA Approval
The approval was based on data from the HOPE-B trial that included 54 male participants with severe or moderately severe hemophilia B.
Combination Regimen Highly Effective for Acquired Hemophilia A
Researchers sought to determine whether CyDRi would be a safe and effective treatment for patients with acquired hemophilia A.
Assay Developed for the Measurement of Anti-Factor VIII Antibodies in Patients With Hemophilia A
Researchers sought to develop an assay for measuring neutralizing inhibitors and non-neutralizing antibodies in patients with hemophilia A.
Physical Activity and Fitness Appears Lower Among Patients With Moderate to Severe Hemophilia
Researchers sought to determine the rates of physical activity and fitness in patients with moderate to severe hemophilia.
Stable Clinical Outcomes Seen With Octocog Alfa Prophylaxis in Hemophilia A
Researchers sought to determine whether prophylaxis with octocog alfa would lead to stable bleeding rates in patients with hemophilia A.
VWF Binding Aptamer Demonstrates Benefit in Type 2B Von Willebrand Disease
Researchers sought to determine whether rondoraptivon pegol would improve VWF and factor VIII levels in patients with type 2B von Willebrand disease.
FDA Accepts Resubmitted BLA for Valoctocogene Roxaparvovec for Hemophilia A
Valoctocogene roxaparvovec is administered as a single infusion to produce clotting factor VIII.
VWF Variants Predict Desmopressin Response Among Patients With Von Willebrand Disease
Researchers sought to determine whether the VWF gene variant would be predictive of desmopressin response in patients with VWD.
Non-Alcoholic Fatty Liver Disease Prevalent Among Patients With Hemophilia
Researchers sought to determine the prevalence of NAFLD and associated factors in patients with hemophilia.
Intranasal Desmopressin Compared With Exercise in Mild Hemophilia A
Researchers sought to compare exercise with intranasal desmopressin to examine changes in factor VIII activity in adolescent male patients with mild hemophilia A.
Tranexamic Acid Prophylaxis Does Not Improve Bleeding Risk for Thrombocytopenia in Hematologic Malignancies
Researchers sought to determine whether prophylactic tranexamic acid would improve bleeding outcomes in patients treated for hematologic malignancy at risk of thrombocytopenia.
Valoctocogene Roxaparvovec BLA Resubmitted for Hemophilia A
Valoctocogene roxaparvovec is an investigational adeno-associated virus gene therapy.
Lack of Treatment Consensus Highlights Unmet Need in Prenatal, Neonatal Alloimmune Thrombocytopenia
Researchers sought to describe contemporary management across international centers and evaluate outcomes among patients with FNAIT.
Real-World Analysis Shows Emicizumab Is Safe, Effective in Pediatric Patients With Hemophilia A
Researchers sought to determine whether emicizumab would be effective in treating pediatric patients with hemophilia A.
Including a Clinical Pharmacists Beneficial to Hemophilia Care Team
Researchers sought to determine whether incorporating a clinical pharmacist into the comprehensive care model for patients with hemophilia would improve outcomes.
FLT180a May Improve Factor IX Levels in Patients With Hemophilia B
Researchers sought to determine whether gene therapy FLT180a would improve factor IX levels in patients with hemophilia B.
Emicizumab Prophylaxis Improves Joint Health in Patients With Hemophilia A
Researchers sought to determine whether there were improvements in joint health in patients with hemophilia A taking emicizumab prophylaxis therapy.
Study Compares Physical Activity Monitoring in Young Patients With Hemophilia
Researchers compared a consumer-grade activity monitor and a research-grade accelerometer for measuring activity in patients with hemophilia.
My Life, Our Future: Large Scale Genotyping Analysis of Patients With Hemophilia
Researchers sought to improve the understanding of hemophilia by conducting a wide-scale genotype analysis for patients in the United States.
New Study Characterizes Clinical and Financial Burden in Severe Hemophilia A
Researchers sought to determine the clinical and financial burden of patients with severe hemophilia A.
Rebinyn Approval for Hemophilia B Expanded to Include Routine Prophylaxis
Rebinyn is a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life.
Recombinant von Willebrand Factor Prophylaxis May Reduce ABR in Patients With von Willebrand Disease
Researchers sought to determine whether prophylaxis with recombinant VWF would lead to a decrease in annualized bleed rate in patients with VWD.
Flow Cytometry-Based Method of Diagnosis Developed for Vaccine-Induced Immune Thrombotic Thrombocytopenia
Researchers sought to determine whether an assay using flow cytometry may help to diagnose patients who have vaccine-induced immune thrombotic thrombocytopenia.
Outcomes With Extended Half-Life rFVIIIFc in Previously Untreated Hemophilia A
Researchers sought to determine whether extended half-life recombinant factor VIII would lead to a lower ABR in pediatric patients with severe hemophilia A.
Fibrinogen in Acute Posttraumatic Hypofibrinogenemia in Severe Brain Injury
In a randomized clinical trial, researchers evaluated clinical outcomes following fibrinogen administration in patients with severe TBI and concurrent hypofibrinogenemia.
ProvayBlue Now Available in New Single-Dose Vials for Methemoglobinemia
The new ProvayBlue presentation is supplied in a box of five 10mL single-dose vials; each vial contains 50mg of methylene blue.
Long-Term Analysis of SCT800 in Patients With Severe Hemophilia A
Researchers sought to assess SCT800 in patients with severe hemophilia A.
Fondaparinux Appears More Cost Effective Than Argatroban in Suspected Heparin-Induced Thrombocytopenia
Researchers sought to determine whether fondaparinux would be a more cost-effective treatment compared with argatroban in patients with suspected HIT.
Older Patients With Hemophilia Experience Lower Quality of Life and More Comorbidities
Researchers sought to determine whether older patients with hemophilia would have similar quality of life scores and comorbidities compared with younger patients.
Circulating Extracellular Vesicles and Factor VIIa Treatment in Patients With Hemophilia
Researchers characterized the abundance and impacts of extracellular vesicles associated with recombinant factor VIIa treatment in patients with hemophilia.
Use of a Smart Medical Internet of Things System on Quality of Life in Patients With Hemophilia
Researchers sought to determine whether home nursing based on smart medical Internet of Things systems could improve the quality of life of patients with hemophilia.
Long-Term Prophylaxis Cost-Effective for Von Willebrand Disease
Researchers sought to determine whether long-term prophylaxis against bleeds in patients with von Willebrand disease would be cost effective.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Bleeding Disorders
Loading... 
Loading...